PATIENT POWER INTERVIEWS DR. RUBEN MESA ABOUT FEDRATINIB APPROVAL

  • MPNRF | April 6, 2021

    “BREAKING NEWS: The FDA has approved fedratinib as a new treatment option for myelofibrosis patients. Watch now as our Editorial and Community Director, Rebecca Seago-Coyle, sits down with Dr. Ruben Mesa, Director of Mays Cancer Center at UT Health San Antonio MD Anderson, to talk about what this approval means for myelofibrosis patients, how to know if fedratinib is right for you, possible side effects, and more!”